Investigating a new target for treating neuropathic pain
α9α10 Nicotinic Acetylcholine Receptors in neuropathic pain
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-10980834
This study is looking at how a specific receptor in the body affects nerve pain, with the goal of creating new medications that can help relieve pain without the side effects of opioids, so that people suffering from neuropathic pain can find better treatment options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-10980834 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of α9α10 nicotinic acetylcholine receptors in neuropathic pain, a condition that affects many adults. The researchers aim to develop new drugs that can effectively block these receptors to alleviate pain without the adverse effects associated with current opioid treatments. By using advanced techniques to screen for potential drug candidates, the study seeks to overcome existing challenges in creating effective pain relief options. Patients may benefit from innovative therapies that target this specific receptor pathway.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults suffering from neuropathic pain who have not found relief with current treatments.
Not a fit: Patients who do not experience neuropathic pain or have other types of pain may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for neuropathic pain.
How similar studies have performed: Previous research has shown promise in targeting similar receptors for pain management, indicating potential for success in this approach.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RILEY, ANDREW — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: RILEY, ANDREW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.